Israel National NewsHealth
FDA Approves Teva's Once-Monthly Schizophrenia Injection WELTRUZA
Summarized from Israel National News by baba
RightNeutral tone
Plus
Teva Pharmaceuticals received FDA approval for WELTRUZA, a new once-monthly injectable schizophrenia treatment for adults. The drug, containing olanzapine, uses sustained-release technology and does not require post-injection medical observation, aiming for greater patient convenience. Clinical trials showed significant symptom improvement and no cases of PDSS, a known complication of similar treatments. Teva plans to launch WELTRUZA in the U.S. soon and is seeking European approval.
The story in 6 lines · by baba
- The FDA approved Teva's WELTRUZA, a new once-monthly injectable schizophrenia treatment.
- WELTRUZA contains olanzapine and uses sustained-release technology for gradual drug delivery.
- Unlike some alternatives, WELTRUZA does not require mandatory medical observation post-injection.
- Clinical trials showed WELTRUZA significantly improved schizophrenia symptoms compared to placebo.
- Long-term safety data found no cases of post-injection delirium and sedation syndrome (PDSS).
- Teva plans to launch WELTRUZA in the U.S. in the coming weeks and is seeking European approval.
Israel National News publishes in English. The key points are summarized above. Read Israel National News’s full report from the link at the top of the page.
Mentioned
